Compile Data Set for Download or QSAR
Report error Found 1553 Enz. Inhib. hit(s) with Target = 'Protein cereblon'
TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560819(US11389438, # 30)
Affinity DataKd: <50nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560820(US11389438, # 31)
Affinity DataKd:  75nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560821(US11389438, # 32)
Affinity DataKd:  75nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560822(US11389438, # 33)
Affinity DataKd:  75nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560823(US11389438, # 34)
Affinity DataKd: <50nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560824(US11389438, # 36)
Affinity DataKd:  75nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560825(US11389438, # 37)
Affinity DataKd:  75nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560826(US11389438, # 38)
Affinity DataKd:  75nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560827(US11389438, # 39)
Affinity DataKd: <50nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560828(US11389438, # 40)
Affinity DataKd: <50nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Mouse)
Chdi Foundation

US Patent
LigandPNGBDBM560829(US11389438, # 70)
Affinity DataKd: <50nMAssay Description:Surface Plasmon Resonance (SPR) assays have been developed to test the affinity (KD) of VHL or CRBN-based compounds to respective recombinant ligase ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM50000309(CHEMBL17516 | 6-Imidazol-1-yl-3,4-dihydro-1H-quino...)
Affinity DataKd:  416nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562109(US11401256, Example 2 | N-Methyl-2-[2-(3-methylimi...)
Affinity DataKd:  40nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562110(US11401256, Example 3 | 2-Ethyl-N-methyl-1-(2-oxo-...)
Affinity DataKd:  190nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562111(US11401256, Example 4 | N-Methyl-1-(2-oxo-1,2,3,4-...)
Affinity DataKd:  49nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562112(US11401256, Example 5 | 3-(1-Methyl-1H-imidazol-5-...)
Affinity DataKd:  677nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562113(US11401256, Example 6 | 2-Benzyl-N-methyl-1-(2-oxo...)
Affinity DataKd:  702nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562114(US11401256, Example 7 | 2-Cyclopropyl-N-methyl-1-(...)
Affinity DataKd:  456nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562115(US11401256, Example 8 | 2-((Benzyloxy)methyl)-N-me...)
Affinity DataKd:  788nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562116(US11401256, Example 9 | 6-(1H-Imidazol-1-yl)-3,4-d...)
Affinity DataKd:  16nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562117(US11401256, Example 10 | 2-(2-Methoxybenzyl)-N-met...)
Affinity DataKd:  10nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562118(US11401256, Example 11 | N-Methyl-1-(2-oxo-1,2,3,4...)
Affinity DataKd:  616nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562119(US11401256, Example 12 | N-Methyl-1-(2-oxo-1,2,3,4...)
Affinity DataKd:  250nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562120(US11401256, Example 13 | 2-(2-Methoxypyridin-4-yl)...)
Affinity DataKd:  31nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562121(US11401256, Example 14 | 6-(5-Phenyl-1H-imidazol-1...)
Affinity DataKd:  9nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562122(US11401256, Example 15 | 2-(Hydroxymethyl)-N-methy...)
Affinity DataKd:  11nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562123(US11401256, Example 16 | 2-(2-(Cyclopropanecarboxa...)
Affinity DataKd:  27nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562124(US11401256, Example 17 | Ethyl 5-(methylcarbamoyl)...)
Affinity DataKd:  10nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562125(US11401256, Example 18 | 2-(2-Aminoethyl)-N-methyl...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562126(US11401256, Example 19 | Methyl 4-((2-oxo-1,2,3,4-...)
Affinity DataKd:  30nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562127(US11401256, Example 20 | N-Methyl-2-(morpholine-4-...)
Affinity DataKd:  10nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562128(US11401256, Example 21 | (RS)—N-(7-Oxo-5,6,7,...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562129(US11401256, Example 22 | Methyl 2-(2-methoxypyridi...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562130(US11401256, Example 23 | 2-(6-Methoxypyridin-2-yl)...)
Affinity DataKd:  15nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562131(US11401256, Example 24 | 2-(6-Methoxypyridin-3-yl)...)
Affinity DataKd:  12nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562132(US11401256, Example 25 | 2-(4-Methoxypyridin-2-yl)...)
Affinity DataKd:  3nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562133(US11401256, Example 26 | 2-(2-Methoxypyridin-3-yl)...)
Affinity DataKd:  15nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562134(US11401256, Example 27 | 6-(5-(4-Methoxyphenyl)-1H...)
Affinity DataKd:  22nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562135(US11401256, Example 28 | 2-Isopropyl-N-methyl-1-(7...)
Affinity DataKd:  8nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562136(US11401256, Example 29 | 2-(2-Methoxy-4-pyridyl)-N...)
Affinity DataKd:  35nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562137(US11401256, Example 30 | 2-(2-Acetylphenyl)-N-meth...)
Affinity DataKd:  579nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562138(US11401256, Example 31 | N-Methyl-2-[2-(methylcarb...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562139(US11401256, Example 32 | 2-(3-Methoxyphenyl)-N-met...)
Affinity DataKd:  17nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562139(US11401256, Example 32 | 2-(3-Methoxyphenyl)-N-met...)
Affinity DataKd:  45nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562141(US11401256, Example 34 | 2-[4-(Acetamidomethyl)phe...)
Affinity DataKd:  431nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562142(US11401256, Example 35 | 2-(2-Fluoro-5-methoxy-phe...)
Affinity DataKd:  14nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562143(US11401256, Example 36 | 2-[2-(Hydroxymethyl)pheny...)
Affinity DataKd:  39nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562144(US11401256, Example 37 | 2-(2-Acetamidophenyl)-N-m...)
Affinity DataKd:  439nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562145(US11401256, Example 38 | 2-(2-Aminophenyl)-N-methy...)
Affinity DataKd:  6nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562146(US11401256, Example 39 | 2-(4-Methoxy-6-methyl-2-p...)
Affinity DataKd:  6nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

Displayed 1 to 50 (of 1553 total ) | Next | Last >>
Jump to: